NCT05486975

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0591CP Cell in Patients With Relapsed and/or Refractory Multiple Myeloma

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.

Conditions

• Relapsed and/or Refractory Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CT0591CP Cells	CT0591CP cells

Timeline

• Start date: 2022-08-10
• Primary completion: 2025-01-29
• Completion: 2025-01-29
• First posted: 2022-08-04
• Last updated: 2023-04-12

Locations

1 site across 1 country: China